Abstract: The present invention provides methods of identifying an increased risk of a dopamine dysregulation disorder in a human subject, including identifying increased risk of dementia, Parkinson's disease, Huntington's, epilepsy, mania, attention deficit disorder, anxiety, dyslexia, schizophrenia, depression, obsessive-compulsive disorders, alcoholism, obesity, addiction disorders, pathological gambling, attention deficit hyperactivity disorder, bipolar disorder, Tourette syndrome, substance dependence, sub stance abuse, substance overdose, and substance-related death.

Abstract: A method for predicting a subject's risk factors for dopamine transporter or SLC6A3-related disorders. The method includes detecting the allelic status of one or more polymorphisms in a nucleic acid sample of the subject. The present invention also provides a related kit, comprising an assay for detecting the allelic status of one or more polymorphisms in a nucleic acid sample of a subject.

Abstract: Diagnostic and prognostic methods, compositions, assays, and kits useful for predicting the phenotype of subjects who have, or are at risk of developing, a mental disorder. The methods also include predicting the prognostic outcome of a subject's mental disorder as well as the subject's responsiveness to drug treatments for the mental disorder. The methods and kits include determining the allelic status of polymorphisms in the MAOA, TPH2 and DRD2 genes.